Avoro Capital Advisors LLC Takes $32.77 Million Position in Lexeo Therapeutics, Inc. $LXEO

Avoro Capital Advisors LLC acquired a new stake in shares of Lexeo Therapeutics, Inc. (NASDAQ:LXEO) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 3,300,000 shares of the company’s stock, valued at approximately $32,769,000. Lexeo Therapeutics comprises approximately 0.3% of Avoro Capital Advisors LLC’s holdings, making the stock its 29th biggest holding.

A number of other large investors have also recently made changes to their positions in the stock. Balyasny Asset Management L.P. purchased a new stake in shares of Lexeo Therapeutics during the second quarter valued at $16,117,000. Citadel Advisors LLC grew its holdings in shares of Lexeo Therapeutics by 3.1% during the third quarter. Citadel Advisors LLC now owns 3,719,043 shares of the company’s stock valued at $24,694,000 after buying an additional 111,076 shares during the last quarter. Vestal Point Capital LP grew its holdings in shares of Lexeo Therapeutics by 0.7% during the third quarter. Vestal Point Capital LP now owns 3,250,000 shares of the company’s stock valued at $21,580,000 after buying an additional 21,839 shares during the last quarter. State Street Corp grew its holdings in shares of Lexeo Therapeutics by 485.1% during the fourth quarter. State Street Corp now owns 3,187,722 shares of the company’s stock valued at $31,654,000 after buying an additional 2,642,877 shares during the last quarter. Finally, Vanguard Group Inc. boosted its holdings in Lexeo Therapeutics by 11.2% in the third quarter. Vanguard Group Inc. now owns 2,226,290 shares of the company’s stock valued at $14,783,000 after purchasing an additional 223,424 shares during the last quarter. 60.67% of the stock is owned by hedge funds and other institutional investors.

Lexeo Therapeutics Stock Performance

NASDAQ:LXEO opened at $4.75 on Wednesday. Lexeo Therapeutics, Inc. has a one year low of $3.60 and a one year high of $10.99. The firm has a market cap of $372.97 million, a price-to-earnings ratio of -3.28 and a beta of 1.38. The firm’s fifty day moving average is $5.48 and its two-hundred day moving average is $6.98.

Lexeo Therapeutics (NASDAQ:LXEO) last posted its quarterly earnings results on Monday, May 11th. The company reported ($0.25) EPS for the quarter, beating the consensus estimate of ($0.29) by $0.04. As a group, equities research analysts predict that Lexeo Therapeutics, Inc. will post -1.23 earnings per share for the current fiscal year.

Insider Activity

In other news, CEO Richard Nolan Townsend sold 55,000 shares of the stock in a transaction dated Monday, April 6th. The shares were sold at an average price of $5.69, for a total transaction of $312,950.00. Following the sale, the chief executive officer directly owned 340,106 shares of the company’s stock, valued at $1,935,203.14. This represents a 13.92% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 59,644 shares of company stock worth $336,462. Corporate insiders own 2.00% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have commented on the stock. Wall Street Zen raised shares of Lexeo Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, May 16th. Weiss Ratings raised shares of Lexeo Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, June 11th. Finally, Chardan Capital reaffirmed a “buy” rating and issued a $17.00 price target on shares of Lexeo Therapeutics in a report on Monday, May 11th. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Lexeo Therapeutics presently has an average rating of “Moderate Buy” and an average target price of $20.14.

Lexeo Therapeutics Profile

Lexeo Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to developing novel, precision‐designed therapies for central nervous system disorders. The company’s research platform leverages advanced medicinal chemistry to create next‐generation psychedelic-inspired compounds aimed at treating a range of mental health conditions, including anxiety, depression and substance use disorders.

The company’s pipeline features proprietary synthetic molecules engineered to target specific neural pathways while improving safety and tolerability profiles over traditional treatments.